[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hereditary-breast-and-ovarian-cancer-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hereditary-breast-and-ovarian-cancer-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100584663","the-fyi-on-mri-a-multilevel-decision-support-intervention-for-screening-breast-mri-100584663",false,"NCT06892275","The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI","Inclusion Criteria:\n\n* female\n* aged 18-74 years\n* self-identifying as Black and\u002For Latina\n* no personal history of breast cancer\n* English- or Spanish-speaking\n* having received a mammogram with normal results in the last 12 months\n* ≥20% lifetime breast cancer risk per the NCI Breast Cancer Risk Assessment Tool (BCRAT)\n\nExclusion Criteria:\n\n* aged \\\u003C18 or ≥75\n* pregnancy","FEMALE","18 Years","74 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to test the impact of a multilevel decision support intervention on informed decisions about breast MRI among high-risk Black and Latina women. Participants (N=80) will be randomized to (1) enhanced usual care (risk assessment + referral to nurse practitioner) or (2) decision support (enhanced usual care + decision aid). Assessments will take place at baseline (T0) and 1-month post-intervention (T1). The primary outcome is informed decisions about breast MRI at T1.",[26,27,28,29],"Breast Neoplasm Female","Early Detection of Cancer","Hereditary Breast and Ovarian Cancer Syndrome","Magnetic Resonance Imaging","RECRUITING","2025-09-26",{"date":33,"type":34},"2025-09-30","ACTUAL",{"date":36,"type":34},"2025-06-01",{"date":38,"type":20},"2027-12",{"name":40,"class":41},"Georgetown University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100595984","development-and-validation-of-an-ovarian-cancer-risk-prediction-model-for-family-members-of-ovarian-cancer-probands-100595984","NCT07039552","Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands","Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands With BRCA1\u002F2 Germline Mutations","Inclusion Criteria:\n\n* Pathologically diagnosed with ovarian malignant tumor.\n\n  * Identified as carriers of BRCA1\u002F2 germline pathogenic or likely pathogenic mutations through genetic testing, in accordance with the \"Standards and Guidelines for the Interpretation of Sequence Variants\" (2015 Edition) of the American College of Medical Genetics and Genomics (ACMG).\n\n    * Age of 18 years or older. ④ Voluntary participation in this research and signing of the informed consent form.\n\nExclusion Criteria:\n\n* ① Patients who refuse to provide necessary information.",{"count":51,"type":20},10000,"OBSERVATIONAL","Ovarian cancer is the gynecological malignancy with the highest fatality rate, seriously threatening the life and health of women. One of the main reasons for its high fatality rate is that approximately 70% of patients are diagnosed at an advanced stage. Fortunately, about 1\u002F5 of ovarian cancers are associated with genetic factors, providing us with an opportunity to screen high-risk populations and thereby prevent and diagnose the disease at an early stage and reduce the disease burden.\n\nCurrently, research related to hereditary ovarian cancer in China is still very scarce, and clinical practice relies on data from foreign studies. However, hereditary tumors have distinct regional and ethnic characteristics, making it urgent to conduct clinical research based on the Chinese population to guide clinical practice in China. Current research suggests that approximately 50% - 60% of hereditary ovarian cancers are closely related to the BRCA1\u002F2 genes. Therefore, accurately assessing the risk of ovarian cancer in BRCA1\u002F2 germline mutation carriers is of great significance for the prevention and treatment of hereditary ovarian cancer.",[28,55],"BRCA Mutations",[57,58],"BRCA1 or BRCA2 germline mutations","hereditary ovarian cancer","2025-06-17",{"date":61,"type":34},"2025-06-26",{"date":63,"type":34},"2016-01-01",{"date":65,"type":20},"2035-12-30",{"name":67,"class":41},"Peking University Third Hospital"]